Table 3. Frequency of main local and systemic adverse events.
| Type of AE | Group I (35 mg), N=7 | Group II (70 mg), N=7 |
|---|---|---|
|
Local | ||
| Pain in lower abdomen | 6 (85.7%) | 6 (85.7%) |
| Tumour bleeding | 1 (14.3%)a | 1 (14.3%) |
| Genital warm | 2 (28.6%) | 1 (14.3%) |
|
Systemic | ||
| Hot flashes | 7 (100%) | 7 (100%) |
| Localised itching | 6 (85.7%) | 6 (85.7%) |
| Localised rash | 6 (85.7%) | 6 (85.7%) |
| Extensive itching | 3 (42.9%) | 6 (85.7%) |
| Hypotension | 2 (28.6%) | 6 (85.7%) |
| Tachycardia | 3 (42.9%) | 5 (71.4%) |
| Localised bumps | 3 (42.9%) | 4 (57.1%) |
| Localised facial oedema | 3 (42.9%) | 3 (42.9%) |
| Headache | 2 (28.6%) | 3 (42.9%) |
| Nausea | 2 (28.6%) | 3 (42.9%) |
| Fever | 2 (28.6%) | 2 (28.6%) |
| Localised cramps | 2 (28.6%) | 2 (28.6%) |
| Extensive cramps | 1 (14.3%) | 3 (42.9%) |
| Dizziness | 0 | 4 (57.1%) |
| Metallic flavour | 1 (14.3%) | 3 (42.9%) |
| Extensive bumps | 2 (28.6%) | 1 (14.3%) |
| Extensive rash | 2 (28.6%) | 1 (14.3%) |
| Vomiting | 2 (28.6%) | 1 (14.3%) |
| Allergic reaction | 1 (14.3%)a | 1 (14.3%)a |
| Hypertension | 0 | 2 (28.6%) |
| Anaemia | 1 (14.3%)a | 0 |
a
Grade 3 events.